文献速递前列腺癌

根治性前列腺切除术后持续性前列腺特异性抗原及其对肿瘤学结局的影响

Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
PubMed 文献 · Eur Urol · 2019-02-14

在高容量中心数据库中,根治性前列腺切除术后6周持续性PSA(≥0.1ng/ml)者占8.8%(n=1025)。持续性PSA是转移、死亡和肿瘤特异性死亡的独立预测因素,术后15年MFS、OS、CSS均显著低于PSA不可测者。倾向评分匹配后,挽救性放疗与OS和CSS改善相关。

要点

  • 根治性前列腺切除术后6周持续性PSA(≥0.1ng/ml)者占8.8%(n=1025)。
  • 持续性PSA是转移(HR 3.59)、死亡(HR 1.86)和肿瘤特异性死亡(HR 3.15)的独立预测因素。
  • 持续性PSA患者中,挽救性放疗与OS(HR 0.37)和CSS(HR 0.12)改善相关。

核心结论

  • 根治性前列腺切除术后持续性PSA与更差的肿瘤学结局相关,即转移、死亡和肿瘤特异性死亡。
  • 在持续性PSA患者中,挽救性放疗使OS和CSS改善。

研究设计与样本

  • 在高容量中心数据库中识别根治性前列腺切除术后6周持续性PSA(≥0.1ng/ml)与PSA不可测(<0.1ng/ml)的患者,排除接受新辅助和/或辅助雄激素剥夺治疗(ADT)者。
  • 共识别11604例患者,其中8.8%(n=1025)存在持续性PSA。
  • 采用逻辑回归模型检验持续性PSA的预测因素,Kaplan-Meier分析和Cox回归模型检验持续性PSA对无转移生存(MFS)、总生存(OS)和肿瘤特异性生存(CSS)率的影响。
  • 采用倾向评分匹配(PSM)检验挽救性放疗(SRT)对持续性PSA患者OS和CSS的影响。

主要发现

  • 根治性前列腺切除术后15年,持续性PSA组 vs PSA不可测组的MFS为53.0% vs 93.2%(p<0.001),OS为64.7% vs 81.2%(p<0.001),CSS为75.5% vs 96.2%(p<0.001)。
  • 在多变量Cox回归模型中,持续性PSA是转移(HR 3.59,p<0.001)、死亡(HR 1.86,p<0.001)和肿瘤特异性死亡(HR 3.15,p<0.001)的独立预测因素。
  • 1:1 PSM后,SRT与OS改善(HR 0.37,p=0.02)和CSS改善(HR 0.12,p<0.01)相关。

临床怎么用

  • 作者指出,在持续性PSA患者中,SRT使OS和CSS改善。
  • 作者指出,在经过良好选择的患者中,挽救性放疗可能带来生存获益。

局限性

  • 主要局限性是缺少术后PSA和挽救性ADT持续时间的相关数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Persistent prostate-specific antigen (PSA) represents a poor prognostic factor for recurrence after radical prostatectomy (RP). OBJECTIVE: To investigate the impact of persistent PSA at 6wk after RP on long-term oncologic outcomes and to assess patient characteristics associated with persistent PSA. DESIGN, SETTING, AND PARTICIPANTS: Within a high-volume center database we identified patients who harbored persistent (≥0.1ng/ml) versus undetectable PSA (<0.1ng/ml) at 6wk after RP. Patients with neo- and/or adjuvant androgen-deprivation therapy (ADT) were excluded. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Logistic regression models tested for prediction of persistent PSA. Kaplan-Meier analyses and Cox regression models tested the effect of persistent PSA on metastasis-free survival (MFS), overall survival (OS), and cancer-specific survival (CSS) rates. Propensity score matching (PSM) was performed to test the impact of salvage radiotherapy (SRT) on OS and CSS in patients with persistent PSA. RESULTS AND LIMITATIONS: Of 11 604 identified patients, 8.8% (n=1025) harbored persistent PSA. At 15yr after RP, MFS, OS, and CSS were 53.0% versus 93.2% (p<0.001), 64.7% versus 81.2% (p<0.001), and 75.5% versus 96.2% (p<0.001) for persistent versus undetectable PSA, respectively. In multivariable Cox regression models, persistent PSA represented an independent predictor for metastasis (hazard ratio [HR]: 3.59, p<0.001), death (HR: 1.86, p<0.001), and cancer-specific death (HR: 3.15, p<0.001). SRT was associated with improved OS (HR: 0.37, p=0.02) and CSS (HR: 0.12, p<0.01) after 1:1 PSM. Main limitation is missing data on postoperative PSA and duration of salvage ADT. CONCLUSIONS: Persistent PSA is associated with worse oncologic outcome after RP, namely, metastasis, death, and cancer-specific death. In patients with persistent PSA, SRT resulted in improved OS and CSS. PATIENT SUMMARY: We assessed the impact of persistent prostate-specific antigen (PSA) at 6wk after radical prostatectomy on oncologic outcomes. Early persistent PSA was associated with worse metastasis-free survival, overall survival, and cancer-specific survival. Salvage radiotherapy may result in a survival benefit in well-selected patients.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Preisser F, Chun FKH, Pompe RS, et al. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. Eur Urol. 2019. PMID: 30772034. doi:10.1016/j.eururo.2019.01.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。